Dyadic International (NASDAQ:DYAI) Releases Earnings Results, Misses Expectations By $0.03 EPS

Dyadic International (NASDAQ:DYAI) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03), FiscalAI reports. The firm had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $1.34 million. Dyadic International had a negative return on equity of 736.26% and a negative net margin of 239.67%.

Here are the key takeaways from Dyadic International’s conference call:

• Dyadic reports multiple commercial product launches and initial sales — including the Proliant-launched recombinant human albumin, Fermbox-partnered RNase‑free DNase I, first FGF sales, and progress on transferrin, supported by an IBT distribution agreement.
• FY2025 revenue declined to $3.09M (from $3.5M) and net loss widened to $7.36M; the company has ~$8.6M in cash with a stated runway into 2027 and an ATM in place, which creates optionality but potential dilution risk.
• Management is pursuing a capital‑efficient, partner‑led go‑to‑market strategy — profit‑sharing, OEM distribution, and milestone/royalty deals with Fermbox, Proliant, IBT, BRIG BIO and others to scale manufacturing and sales without large capex.
• Its C1 production platform continues to be validated across biopharma collaborations (Gates, CEPI, Scripps, EuVac‑Bio, NIAID, etc.), showing comparable expression and folding to CHO/insect systems and supporting potential licensing, milestones, and vaccine/antibody programs.

Dyadic International Stock Performance

Shares of DYAI opened at $0.70 on Friday. The company has a market capitalization of $25.38 million, a price-to-earnings ratio of -2.80 and a beta of 1.29. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.45. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. The stock has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.95.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.00.

Institutional Trading of Dyadic International

Several institutional investors have recently modified their holdings of DYAI. Geode Capital Management LLC grew its position in shares of Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Dyadic International in the third quarter valued at $190,000. Finally, Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.